Jazz Pharmaceuticals to Report 2022 Fourth Quarter and Full Year Financial Results on March 1, 2023

Rhea-AI Summary

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) will release its financial results for the fourth quarter and full year 2022 on March 1, 2023, following the close of U.S. markets. A live audio webcast is scheduled for 4:30 p.m. ET / 9:30 p.m. GMT to discuss the financial outcomes and provide a business update. Interested individuals can register in advance through the company's website. Following the event, a replay will be available on Jazz's investor section. The company focuses on developing transformative medicines in neuroscience and oncology, with a commitment to addressing unmet medical needs globally.

DUBLIN, Feb. 15, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 fourth quarter and full year financial results on Wednesday, March 1, 2023, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2022 fourth quarter and full year financial results and provide a business and financial update.

Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. 

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.

Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media Contact:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-2022-fourth-quarter-and-full-year-financial-results-on-march-1-2023-301747989.html

SOURCE Jazz Pharmaceuticals plc

FAQ

When will Jazz Pharmaceuticals report its 2022 financial results?

Jazz Pharmaceuticals will report its 2022 financial results on March 1, 2023.

What time will the Jazz Pharmaceuticals earnings call take place?

The Jazz Pharmaceuticals earnings call will start at 4:30 p.m. ET on March 1, 2023.

How can I access the Jazz Pharmaceuticals earnings call?

You can register for the Jazz Pharmaceuticals earnings call on their website under the Investors section.

Is there a replay available for the Jazz Pharmaceuticals earnings call?

Yes, a replay of the earnings call will be available in the Investors section of the Jazz Pharmaceuticals website.